CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $45,510,022 | +89.9% | 1,530,263 | +15.0% | 1.54% | +161.5% |
Q2 2023 | $23,971,339 | +12.2% | 1,330,263 | 0.0% | 0.59% | -14.7% |
Q1 2023 | $21,364,024 | -12.2% | 1,330,263 | 0.0% | 0.69% | -7.2% |
Q4 2022 | $24,343,813 | -6.8% | 1,330,263 | 0.0% | 0.74% | -3.9% |
Q3 2022 | $26,126,000 | +5.3% | 1,330,263 | 0.0% | 0.77% | -9.9% |
Q2 2022 | $24,809,000 | +43.0% | 1,330,263 | +68.3% | 0.86% | +57.6% |
Q1 2022 | $17,345,000 | +3.4% | 790,209 | +33.9% | 0.54% | +1.7% |
Q4 2021 | $16,767,000 | +11.3% | 590,169 | -31.4% | 0.53% | -52.0% |
Q2 2020 | $15,064,000 | +192.8% | 859,802 | +145.7% | 1.11% | +107.1% |
Q1 2020 | $5,145,000 | – | 350,000 | – | 0.54% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |